[{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Drug Innovation Ventures at Emory","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Envelope glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ridgeback Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Ridgeback Biotherapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target